Coronary Artery Disease, Pneumonia Nosocomial
Conditions
Keywords
pneumonia, Coronary Artery Bypass Grafting, coronary artery disease
Brief summary
Observational studies of patients with coronary artery bypass grafting, associated with an unfavorable cardiopulmonary prognosis for at least one year after surgery. This is Prospective, cohort, unblinded, observational comparable single center clinical trial. To compare the clinical, laboratory (including complete blood count, metabolic panel, and specific cardiac, inflammatory, infectious, and endothelial biomarkers), functional (ECG, echocardiography, ultrasound, spirometry, cardiopulmonary exercise testing), and radiological (chest X-ray/CT) phenotypes in patients with coronary artery bypass grafting with and without non-ventilator-associated postoperative, nosocomial pneumonia; to identify the factors of early and 1-years cardiopulmonary prognosis. Increased risk of cardiovascular outcomes is related with the circulatory arrest, artificial circulation, perioperative trauma and respiratory complications of the postoperative period associating to the different severity and duration of the systemic inflammatory response, immune status disorders, hemostasis disorder, endothelial dysfunction, external respiration dysfunction, anatomic and functional disorders in the heart and lungs. Individual predictors of an unfavorable prognosis can be determined at the stage of before and just after surgery to conduct personalized prevention. This study aimed to compare the clinical, laboratory (including complete blood count, metabolic panel, and specific cardiac, inflammatory, infectious, and endothelial biomarkers), functional (ECG, echocardiography, ultrasound, spirometry, cardiopulmonary exercise testing), and radiological (chest X-ray/CT) phenotypes in patients after coronary artery bypass grafting with and without non-ventilator-associated postoperative nosocomial pneumonia; to identify the factors of early and 1-years cardiopulmonary prognosis.
Detailed description
RESEARCH RELEVANCE Cardiovascular diseases (CVD), remain the leading cause of death worldwide. In 2017, mortality from cardiovascular diseases reached 862,895 people, or 587.6 per 100,000 of the population. Coronary artery disease (CAD) holds the leading position in the structure of causes of death from CVD. The annual mortality rate from CAD is 27%, with 42% of all deceased being of working age. Myocardial revascularization is one of the most common surgical procedures for the effective treatment of CAD. In the United States, over 200,000 coronary artery bypass grafting (CABG) surgeries are performed annually, with approximately 14% of patients being rehospitalized within 30 days after discharge and another 10% visiting emergency departments due to surgery-related complications and care issues. Pulmonary complications, primarily pneumonia (3%-42%), account for a significant proportion of the complications. Although pneumonia primarily affects the lungs, growing evidence suggests that it can have a negative impact on many systems and organs, particularly the cardiovascular system. The impact of pneumonia on the starting CVD consist the most evidences. The short-term and long-term impact of nosocomial pneumonia (NP) on the course of determined CVD, especially following myocardial revascularization performed using coronary bypass grafting (CABG) has not been previously assessed, and potential mechanisms have not been studied. It is known that the CABG leads to an enhanced systemic inflammatory response, is associated with nitric oxide deficiency, endothelial dysfunction, and procoagulant activity. Therefore, a postoperative complication in the form of NP in patients with multivessel CAD and not rare anatomic and functional myocardial disorders could potentially lead to a short-term additive enhancement of the inflammatory and endothelial response associated with the surgery, and to long-term activation of immune inflammation after CABG. The consequence of this may be an increased frequency of any complications within one year or more after surgery and a reduction in its effectiveness in reversing signs of coronary and heart failure. However, there is no confirmation of this assumption. The impact of pneumonia complications, such as respiratory failure, on the course of stable CAD is also insufficiently studied. The study will be conducted at the Cardiology Research Institute - a branch of the Federal State Budgetary Scientific Institution "Tomsk National Research Medical Center of the Russian Academy of Sciences" (Cardiology Research Institute of the Tomsk NRMC) in Tomsk, Russia, from December 2024 to June 2027. The study was approved by the Biomedical Ethics Committee of the Cardiology Research Institute of the Tomsk NRMC on December 25, 2024. Informed consent will be obtained from all study participants after the nature, purpose, and potential risks of the study have been explained to them. PRIMARY OBJECTIVE To test the hypothesis that in patients with stable coronary artery disease undergoing CABG, the occurrence of postoperative nosocomial pneumonia is associated with an adverse cardiopulmonary prognosis for at least one year after surgery. SRCONDARY OBJECTIVES To compare the clinical, cellular, secretory, and instrumental profiles, as well as their in-hospital dynamics, between patients with an uncomplicated postoperative course and those complicated by nosocomial pneumonia. To assess the sensitivity, specificity, and diagnostic accuracy of pulmonary and systemic criteria for diagnosing nosocomial pneumonia in patients with CAD following surgical myocardial revascularization; to identify the most specific systemic diagnostic criteria or propose new ones. In a prospective one-year follow-up study of patients with CAD corrected by CABG, to evaluate the impact of nosocomial pneumonia on cardiopulmonary prognosis; to identify in-hospital predictors of an unfavorable prognosis for the purpose of personalized prevention. The effectiveness of the study will be assessed by such a concept as "end point". The primary endpoint was assessed at visits 5, 6, and 7 as the difference in parameters between the groups with pneumonia and without pneumonia and included the frequency of occurrence of one or more cardiovascular and/or respiratory endpoint events.
Interventions
Clinical, laboratory, and instrumental examinations will be performed to achieve the specified primary and secondary endpoints.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age 18 years and older. * Myocardial revascularization for CAD via CABG during the current hospitalization, in accordance with the indications defined by the ESC/EACTS Guidelines on Myocardial Revascularization \[DOI: 10.1093/eurheartj/ehy394\]. * Successful transfer from the intensive care unit to a general ward after surgery. * One or more of the risk factor for nosocomial pneumonia \[doi: 10.15829/1560-4071-2024-6094\]. * Signed informed consent for participation in the study. Pre-operative
Exclusion criteria
* Acute coronary syndrome within the last 1 month. * Combined surgical intervention for infective endocarditis. * Combined valve surgery. * Concomitant pulmonary disease requiring respiratory support prior to surgery. * Presence of a tracheostomy. * Participation in another clinical trial at the time of potential inclusion or within the preceding 3 months. * Diagnosis of malignant neoplasms within the last 5 years. * Life duration of less than 1 year. * HIV infection. Peri-operative
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of combined cardiovascular+respiratory endpoint (percentage); | 12 months | The study will assess the incidence (percentage) of occurrence of combined cardiovascular+respiratory endpoint that includes the following events: * Cardiovascular events: All-cause mortality, cardiovascular mortality, acute myocardial infarction, unstable angina, myocardial revascularization, acute cerebrovascular accident, transient ischemic attack, hospitalization or emergency medical service visit for acute heart failure or decompensation of chronic heart failure, hospitalization for cardiac arrhythmias, new-onset atrial fibrillation. * Respiratory events: Respiratory mortality, hospitalization for broncho-obstructive or broncho-restrictive diseases, new oxygen dependence, initiation of non-invasive or invasive mechanical ventilation, new diagnosis of bronchial asthma or chronic obstructive pulmonary disease n the frequency of occurrence of one or more cardiovascular and/or respiratory endpoint events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Levels of procalcitonin (ng/ml); | 12 months | Difference between groups in the levels of procalcitonin; |
| Levels of interleukins 1 (pg/ml); | 12 months | Difference between groups in the levels of interleukins 1. |
| Changes in immune status (in percent); | 30 days | Difference between groups in the changes in immune status; |
| Level of endothelin-1 (ET-1) (pg/ml); | 6 months | Difference between groups in the level of endothelin-1 (ET-1); |
| Level of presepsin (pg/ml); | 6 months | Difference between groups in the levels of presepsin |
| Interleukins 6(pg/ml); | 6 months | Difference between groups in the levels of interleukins 6; |
| Tumor Necrosis Factor α (TNF-α)(pg/ml); | 6 months | Difference between groups in the levels of TNF-α; |
| Level of vascular endothelial growth factor (VEGF) (pg/ml); | 6 months | Difference between groups in the level of vascular endothelial growth factor (VEGF); |
| Difference between groups in the level of endocan (pg/ml); | 6 months | Level of endocan . |
Countries
Russia
Contacts
Cardiology Research Institute of Tomsk NRMC
Cardiology Research Institute of Tomsk NRMC
Cardiology Research Institute of Tomsk NRMC
Cardiology Research Institute of Tomsk NRMC
Cardiology Research Institute of Tomsk NRMC
Cardiology Research Institute of Tomsk NRMC